Global Multiple Sclerosis Market Hits $31.0 Billion in 2025 with 6.5% CAGR

Multiple sclerosis market was valued at $31.0 billion in 2025 and is projected to reach $57.3 billion by 2035, growing at a CAGR of 6.5% during the forecast period (2026-2035). The multiple sclerosis market growth is driven by increasing demand for disease-modifying therapies, symptomatic treatments, and digital health management solutions across the healthcare sector. The adoption of these therapies and tools is influenced by advances in pharmaceutical development, clinical research, and biologic therapies, along with the increasing use of digital platforms for remote monitoring, telemedicine, and patient adherence tracking. Regulatory frameworks in key markets support the approval, safety, and distribution of MS therapies, which helps expand market adoption.

Browse the full report description of “Multiple Sclerosis Market Size, Share & Trends Analysis Report By Types (PPMS, PRMS, RRMS, SPMS) By Diagnostics Technologies (MRI, Evoked Potential Test, Spinal Fluid Test, and Others) By Mode of Administration (Injectable Agents, Oral Agents, and Intravenous Therapy) By Drug Class (Immunomodulators, and Immunosuppressant) Forecast, 2026-2035.” Of https://www.omrglobal.com/industry-reports/multiple-sclerosis-market

In the United States, policies such as the Food and Drug Administration (FDA) regulatory approvals, orphan drug designations, and incentives for the development of novel therapies guide manufacturers in the development and commercialisation of MS treatments. Compliance with these regulations is critical for disease-modifying therapies, biologics, and emerging digital health tools, encouraging investment in research, clinical trials, and treatment infrastructure. The demand for MS therapies is also supported by healthcare providers and patient advocacy groups focused on improving patient outcomes and reducing disease progression.

In Europe, programs like the European Medicines Agency (EMA) approval processes and government grants for research in neurodegenerative diseases are driving the development and deployment of MS therapies. Countries including Germany, France, and the United Kingdom are establishing regulatory standards and funding mechanisms to support clinical research, therapy approval, and commercialization of disease-modifying treatments and monitoring solutions for relapsing and progressive forms of MS. The combination of policy support, technological development, and cross-industry adoption is contributing to steady growth of the global Multiple Sclerosis market.

 Key Innovators Driving the Multiple Sclerosis Market

The key players in the global multiple sclerosis market include Biogen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA (EMD Serono Inc.), Novartis AG, Sanofi S.A., among others.  These companies are actively developing therapies, disease?modifying treatments, and digital health solutions for MS management, such as telemedicine platforms, remote patient monitoring tools, and AI?assisted clinical decision support systems, shaping the future of MS care and treatment globally.

• In November 2025, Biogen launched Vumerity® Extended?Release (ER) tablets in the U.S., offering an updated oral therapy for relapsing forms of multiple sclerosis. This new formulation improves dosing flexibility and gastrointestinal tolerability, while maintaining efficacy in reducing relapse rates and disease progression.
• In November?2025, Genentech reported Phase?III results for fenebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in both relapsing and primary progressive multiple sclerosis (MS), as announced by Roche. In the first of two pivotal RMS trials (FENhance?2), fenebrutinib met its primary endpoint by reducing annualised relapse rates compared with teriflunomide. Data from the Phase?III FENtrepid study indicated that fenebrutinib was non?inferior to ocrelizumab in delaying confirmed disability progression in primary progressive MS. The data are part of the clinical evaluation supporting regulatory submissions for fenebrutinib in MS treatment.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By End-Users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Biogen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA (EMD Serono Inc.), Novartis AG, Sanofi S.A., among others. 

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Multiple sclerosis market Report Segment

By Type

• Electronic Health Records (EHR)
• Telemedicine
• Health Information System (HIS/HIE)
• mHealth
• Clinical Decision Support System (CDSS)
• Others

By End-Users

• Healthcare Provider
• Healthcare Consumers
• Others

Multiple sclerosis market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/multiple-sclerosis-market